Search Results
Results found for "Zack Zurawski"
- 📰 GPCR Weekly News, February 13 to 19, 2023
From outside to inside and back again: the lysophosphatidic acid-CCN axis in signal transduction.
- 📰 GPCR Weekly News, September 18 to 24, 2023
If you couldn't make it, no sweat – our premium members can always go back and watch the recorded talks
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
This is where seasoned drug hunters separate themselves from the pack—not just knowing the kinetics ,
- 📰 GPCR Weekly News, August 28 to September 3, 2023
pathophysiology and treatment of CNS disorders GPCRs in Oncology and Immunology From outside to inside and back
- 📰 GPCR Weekly News, February 26 to March 3, 2024
a resounding success; we have a waitlist for those eager to attend this course, which wil be coming back
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Welcome back GPCR fans, The pace of GPCR innovation is accelerating at a rate that can be difficult to
- 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei Heptares to take back
- 📰 GPCR Weekly News, November 20 to 26, 2023
with Multispan Cell Engineering and Assay Services $3bn sales potential for drug Sosei Heptares wants back
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
a cold email from a biologist he’d never met, asking if he could synthesize a molecule “when you’re back
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
platform to connect from anywhere in the world And if you go for a Premium Membership , you'll not only back
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
Additionally, DMS is not universally applicable to all proteins; it struggles with proteins that lack
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
This breeds passive execution, second-guessing, and a lack of ownership .
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
with AEF0217 in young adults with Down syndrome Novartis pays Schrödinger $150M, bets billions on the back
- Structural landscape of the Chemokine Receptor system
CKRs can be classified into typical CKRs, atypical CKRs (ACKRs) which lack G-protein signaling, and viral variants of CCL15, namely CCL15L (residues 26-92) and CCL15M (residues 27-92), while the third structure lacks
- From Failed Experiments to Predictive GPCR Models
His lab has already begun using AlphaFold models to identify ligands for targets that lack experimental
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
In every lab, candidates fail not because they lack potency at a receptor, but because they stumble at
- 📰 GPCR Weekly News
We're excited to be back and share our weekly newsletter!
- Adhesion GPCR Consortium Newsletter - May 2024
The excitement I felt when I first attended back in Boston is the same one I feel now that I am the organizer
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
membranes different from mammalian membranes,[9] which can affect receptors’ properties.[10,11] BBVs also lack Since BBVs lack downstream signaling, doing a quantitative lice-cell assay using the same ligand would
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
models, such as deep learning neural networks, are often referred to as "black boxes" because they lack
- Decoding β-Arrestins: from Structure to function
Despite their contributions, these methods often lack cellular auxiliary structures and proteins.












